6f9u › Citations

Crystal structures of sampatrilat and sampatrilat-Asp in complex with human ACE - a molecular basis for domain selectivity.

Cozier GE, Schwager SL, Sharma RK, Chibale K, Sturrock ED, Acharya KR
FEBS J 285 1477-1490 (2018)
Related entries: 6f9r, 6f9t, 6f9v

Cited: 14 times
EuropePMC logo PMID: 29476645

Reviews - 6f9u mentioned but not cited (1)

  1. Considerations for Docking of Selective Angiotensin-Converting Enzyme Inhibitors. Caballero J. Molecules 25 E295 (2020)

Articles - 6f9u mentioned but not cited (4)

  1. Crystal structures of sampatrilat and sampatrilat-Asp in complex with human ACE - a molecular basis for domain selectivity. Cozier GE, Schwager SL, Sharma RK, Chibale K, Sturrock ED, Acharya KR. FEBS J 285 1477-1490 (2018)
  2. Angiotensin-converting enzyme open for business: structural insights into the subdomain dynamics. Cozier GE, Lubbe L, Sturrock ED, Acharya KR. FEBS J 288 2238-2256 (2021)
  3. Prediction of COVID-19 manipulation by selective ACE inhibitory compounds of Potentilla reptant root: In silico study and ADMET profile. Xu Y, Al-Mualm M, Terefe EM, Shamsutdinova MI, Opulencia MJC, Alsaikhan F, Turki Jalil A, Hammid AT, Enayati A, Mirzaei H, Khori V, Jabbari A, Salehi A, Soltani A, Mohamed A. Arab J Chem 15 103942 (2022)
  4. Molecular Basis for Omapatrilat and Sampatrilat Binding to Neprilysin-Implications for Dual Inhibitor Design with Angiotensin-Converting Enzyme. Sharma U, Cozier GE, Sturrock ED, Acharya KR. J Med Chem 63 5488-5500 (2020)


Reviews citing this publication (2)

  1. ACE2 and ACE: structure-based insights into mechanism, regulation and receptor recognition by SARS-CoV. Lubbe L, Cozier GE, Oosthuizen D, Acharya KR, Sturrock ED. Clin Sci (Lond) 134 2851-2871 (2020)
  2. Small molecule angiotensin converting enzyme inhibitors: A medicinal chemistry perspective. Zheng W, Tian E, Liu Z, Zhou C, Yang P, Tian K, Liao W, Li J, Ren C. Front Pharmacol 13 968104 (2022)

Articles citing this publication (7)

  1. Whey-Derived Peptides Interactions with ACE by Molecular Docking as a Potential Predictive Tool of Natural ACE Inhibitors. Chamata Y, Watson KA, Jauregi P. Int J Mol Sci 21 E864 (2020)
  2. Structural characterization and in-silico analysis of Momordica charantia 7S globulin for stability and ACE inhibition. Kesari P, Pratap S, Dhankhar P, Dalal V, Mishra M, Singh PK, Chauhan H, Kumar P. Sci Rep 10 1160 (2020)
  3. ACE-domain selectivity extends beyond direct interacting residues at the active site. Cozier GE, Lubbe L, Sturrock ED, Acharya KR. Biochem J 477 1241-1259 (2020)
  4. In silico analysis of angiotensin-converting enzyme inhibitory compounds obtained from soybean [Glycine max (L.) Merr.]. Ramlal A, Bhat I, Nautiyal A, Baweja P, Mehta S, Kumar V, Tripathi S, Mahto RK, Saini M, Mallikarjuna BP, Saluja S, Lal SK, Subramaniam S, Fawzy IM, Rajendran A. Front Physiol 14 1172684 (2023)
  5. Angiotensin-converting enzyme inhibitory peptides and isoflavonoids from soybean [Glycine max (L.) Merr.]. Ramlal A, Nautiyal A, Baweja P, Kumar V, Mehta S, Mahto RK, Tripathi S, Shanmugam A, Pujari Mallikarjuna B, Raman P, Lal SK, Raju D, Rajendran A. Front Nutr 9 1068388 (2022)
  6. Computational Studies of Hydroxychloroquine and Chloroquine Metabolites as Possible Candidates for Coronavirus (COVID-19) Treatment. Vaidya NA, Vyas R. Front Pharmacol 11 569665 (2020)
  7. Structural basis for the inhibition of human angiotensin-1 converting enzyme by fosinoprilat. Cozier GE, Newby EC, Schwager SLU, Isaac RE, Sturrock ED, Acharya KR. FEBS J 289 6659-6671 (2022)


Quick links